vadimezan has been researched along with Breast Cancer in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H; Jiang, Z; Liu, J; Liu, Z; Wang, H; Zhang, C; Zhang, J | 1 |
| Bertelsen, LB; Bohn, AB; Falborg, L; Horsman, MR; Shen, YY; Stødkilde-Jørgensen, H | 1 |
| Boerner, SA; Hunsberger, S; Lorusso, PM | 1 |
| Baguley, BC; Cao, Z; Ching, LM; Jameson, MB; Kieda, C; Zwain, S | 1 |
1 trial(s) available for vadimezan and Breast Cancer
| Article | Year |
|---|---|
Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Blotting, Northern; Breast Neoplasms; Cells, Cultured; Chemokine CXCL10; Chemokines, CXC; Colonic Neoplasms; Endothelium, Vascular; Female; Humans; Interferons; Mice; Mice, Inbred C57BL; Ovarian Neoplasms; RNA, Messenger; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones | 2002 |
3 other study(ies) available for vadimezan and Breast Cancer
| Article | Year |
|---|---|
Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
Topics: Antineoplastic Agents; Apoptosis; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Proto-Oncogene Proteins c-mdm2; Tumor Suppressor Protein p53; Xanthones | 2017 |
Treatment with a vascular disrupting agent does not increase recruitment of indium labelled human endothelial outgrowth cells in an experimental tumour model.
Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Carcinoma; Cell Movement; Cell Survival; Cell Tracking; Cells, Cultured; Disease Models, Animal; Endothelial Cells; Female; Fetal Blood; Humans; Indium Radioisotopes; Mice; Mice, Nude; Stilbenes; Xanthones | 2014 |
Clinical development of vascular disrupting agents: what lessons can we learn from ASA404?
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase III as Topic; Data Interpretation, Statistical; Drug Synergism; Female; Humans; Lung Neoplasms; Molecular Targeted Therapy; Neoplasms; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Treatment Failure; Vascular Endothelial Growth Factor A; Xanthones | 2011 |